Skip to main content
Springer logoLink to Springer
. 2023 Jan 3;35(6):1375–1376. doi: 10.1007/s40520-022-02319-1

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis

Nicholas Fuggle 1, Nasser Al-Daghri 2, Olivier Bock 3,4, Jaime Branco 5, Olivier Bruyère 6, Enrique Casado 7, Etienne Cavalier 8, Bernard Cortet 9, Maarten de Wit 10, Andrea Giusti 11, Philippe Halbout 4, Nicholas C Harvey 1,12, Mickaël Hiligsmann 13, Jean-Marc Kaufman 14, Andreas Kurth 15, Stefania Maggi 16, Radmila Matijevic 17, Salvatore Minisola 18, Santiago Palacios 19, Régis Pierre Radermecker 20, Friederike Thomasius 21, Sansin Tuzun 22, Nicola Veronese 23, John A Kanis 24,25, Jean-Yves Reginster 5, René Rizzoli 3, Cyrus Cooper 1,9,26,
PMCID: PMC10200775  PMID: 36595210

Correction: Aging Clinical and Experimental Research (2022) 34:2625–2634 10.1007/s40520-022-02272-z

In the published article, the author would like to update the following lines from

Gastrointestinal adverse events were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal.

to

History of Gastrointestinal symptoms were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal

in the published article.

The original article has been updated.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Aging Clinical and Experimental Research are provided here courtesy of Springer

RESOURCES